双算法集成框架揭示了青伟智通在慢性胃炎中的双重机制
Zhijie Shu1, Ying Huang2, Yujie Xi2
1State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
清维智通微药丸 (QWZT) 通过调节胃肠平滑肌肉和减少炎症,有效治疗慢性胃炎. 这项研究揭示了QWZTT.
科学领域:
- 药理学和中国传统医学 (TCM)
- 计算生物学和实验验证验证
背景情况:
- 慢性胃炎 (CG) 涉及胃粘膜失衡,目前FDA批准的药物对抗性菌株和无法治疗的途径的有效性有限.
- 传统中医 (TCM) 和清维智通微药 (QWZT) 一样,为CG提供了多目标优势,但其机制需要阐明.
- 现有的疗法未能解决不可治疗的途径,如CG中的炎症和自身免疫缩.
研究的目的:
- 阐明青伟智通微药丸 (QWZT) 在治疗慢性胃炎 (CG) 的药理机制.
- 通过分析可用药和不可用药的途径,将QWZT的机制与FDA批准的药物区分开来.
- 通过胃肠功能和炎症的实验模型验证计算预测.
主要方法:
- 采用了一个双算法框架,集成结构-目标-路径相似性和多目标扰动算法.
- 对QWZT与FDA药物的相似性进行了分析,通过胃肠平滑肌体实验验验证.
- 通过使用QWZT独特的能力,在LPS诱导的炎症模型 (RAW264.7和GES-1细胞) 中验证,研究了不可治疗的途径.
主要成果:
- 结构-目标-通路相似性算法识别了具有发动机械机制的QWZT化合物,并通过光滑肌肉反应实验验证.
- 多目标扰动算法揭示了QWZT对不可抗药的免疫/炎症网络的强有力的破坏.
- 在LPS受损细胞中,QWZT显著降低了炎症标志物 (NO,IL-6,TNF-α),其中被确定为关键化合物的和柏柏林.
结论:
- QWZT通过肌肉和多巴胺D2受体 (DRD2) 调节胃肠平滑肌肉,并通过减少NO,IL-6和TNF-α来发挥抗炎作用.
- 该研究提供了一种新的综合方法,将计算算法和实验验证相结合,以了解TCM机制.
- QWZT通过对可药物和不可药物通路的多目标调节,显示出有效治疗慢性胃炎的巨大潜力.
相关概念视频
01:17Gastritis-II: Pathophysiology
1.1K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.1K
01:28Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
01:23Gastritis III: Clinical Manifestations and Management
1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
01:26Peptic Ulcer Disease IV: Management
407
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
407
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.1K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.1K
01:30Peptic Ulcer Disease I: Introduction
719
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
719